New Collaboration Seeks to Accelerate Development of Antibody-Drug Conjugates
February 9th 2024Samsung Biologics will provide antibody development and drug substance manufacturing services for LegoChem Biosciences' antibody-drug conjugate program with hopes of submitting an Investigational New Drug application to the FDA in 2025.
CheckMate -8HW Trial Data Show Survival Improvement With Opdivo, Yervoy Combo in Colorectal Cancer
January 22nd 2024Opdivo (nivolumab) with Yervoy (ipilimumab) improved progression-free survival in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer.
Blenrep Shows Promise in DREAMM-7 Phase 3 Trial for Relapsed, Refractory Multiple Myeloma
November 30th 2023DREAMM-7 was a Phase 3, multicenter, open-label, randomized trial analyzing the efficacy and safety of Blenrep plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously administered at least one prior line of treatment.
Boehringer Ingelheim Delivers Promising Results in Phase II Chronic Kidney Disease Trial
November 6th 2023BI 690517 is a novel, potent, highly selective aldosterone synthase inhibitor that reduces the progression of kidney damage and lowers the risk of cardiovascular events in patients with chronic kidney disease.